Upifitamab Biosimilar - Research Grade

Human

SLC34A2

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

Upinitatug Biosimilar - Research Grade (ICH5959)

https://www.imgt.org/mAb-DB/

ICH3002

O95436

Blue ice

This is a research-grade biosimilar of upifitamab: an unconjugated, non-therapeutic recombinant analog of the originator antibody built around the sodium-dependent phosphate transporter NaPi2b (SLC34A2), supplied for research use only and not for human or veterinary use. The originator is an antibody-drug conjugate under investigation in ovarian and other NaPi2b-expressing cancers; this analog reproduces the antigen-binding specificity in a human IgG1-kappa format without any cytotoxic payload, so it functions purely as a binding reagent. It is useful as an isotype-matched, target-defined tool for characterizing NaPi2b expression, benchmarking anti-NaPi2b binders, and as a naked-antibody control against payload-conjugated constructs in ADC development workflows. It supports flow cytometry, immunoassays, binding and blocking studies, and cell-based assays, and can serve as a positive control in receptor-detection or internalization experiments. Available bulk from milligram to gram scale with low-endotoxin research grade (<1 EU/mg) and ultra-low-endotoxin (<0.5 EU/mg) options suitable for demanding in-vitro and preclinical applications. It is a research analog, not the clinical drug. SLC34A2 encodes NaPi2b (NaPi-IIb), a sodium-dependent inorganic phosphate cotransporter of the SLC34 family. It couples the inward movement of sodium down its electrochemical gradient to the uptake of divalent phosphate across the apical membrane, contributing to systemic phosphate homeostasis. NaPi2b is highly expressed on the apical surface of alveolar type II pneumocytes, where it participates in surfactant phospholipid production, and in the small intestine, mammary gland, and other epithelia. Loss-of-function mutations cause pulmonary alveolar microlithiasis and testicular microlithiasis, reflecting its role in phosphate transport. In oncology, NaPi2b is markedly overexpressed on the cell surface of a large fraction of epithelial ovarian cancers and non-squamous non-small cell lung cancers while showing restricted normal-tissue accessibility, making it an attractive tumor-associated antigen for antibody and ADC targeting.

Sodium-phosphate transport protein 2B, Na(+)-dependent phosphate cotransporter 2B, NaPi3b, Sodium/phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, NaPi-2b, Solute carrier family 34 member 2, Sodium-dependent phosphate transport protein 2B

Detects human SLC34A2

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Upifitamab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Upifitamab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Upifitamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Upifitamab that binds human SLC34A2.